These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32785913)

  • 21. Immunotherapy for advanced hepatocellular carcinoma, where are we?
    Zhang L; Ding J; Li HY; Wang ZH; Wu J
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 23. [Lenvatinib:new molecular targeted therapy of hepatocellular carcinoma -the progress and future perspective].
    Kobayashi M
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(1):36-44. PubMed ID: 30626852
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experience of Treatment with Lenvatinib in Patients with Advanced HCC-A in a Single Institution].
    Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Kawai K; Inatome J; Murakami K; Naito A; Kagawa Y; Masuzawa T; Takeno A; Hata T; Egawa C; Murata K
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2101-2103. PubMed ID: 32157073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
    Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    Chen SC; Chao Y; Yang MH
    Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
    [No Abstract]   [Full Text] [Related]  

  • 29. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo A; Dadduzio V; Ricci AD; Massari F; Di Federico A; Gadaleta-Caldarola G; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):371-378. PubMed ID: 34167433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies.
    Bévant K; Coulouarn C
    EBioMedicine; 2020 Apr; 54():102737. PubMed ID: 32268278
    [No Abstract]   [Full Text] [Related]  

  • 31. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
    Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
    Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
    Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
    Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
    Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
    Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
    PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.